Literature DB >> 3013153

Genetic differences in the resistance of rats to isoprenaline-induced heart lesions.

M Mráz, E Faltová, D Lincová, J Sedivý, N Gaier, E Mühlbachová, M Cernohorský, A Vrána.   

Abstract

Two strains of rats were obtained by selective breeding: the IR strain, resistant to isoprenaline-induced myocardial lesions and the IS strain, sensitive to this damage. The IR rats grew more slowly, the weight of their adipose tissue was higher and the weight of m. soleus was less than that of the IS rats. The IR rats had a higher content of triglycerides in the serum and a lower isoprenaline-stimulated lipolytic activity of adipose tissue in vitro. The basal NEFA level in the serum and its rise after the administration of isoprenaline in vivo did not differ between the strains. The IR rats had a higher content of glycogen in the heart and in the muscle. After the administration of isoprenaline the glycogen content decreased more slowly in IR rats. The findings indicate a considerable importance of the glycogen stores in the heart for the resistance of myocardium to damage.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3013153     DOI: 10.1007/bf01907429

Source DB:  PubMed          Journal:  Basic Res Cardiol        ISSN: 0300-8428            Impact factor:   17.165


  22 in total

1.  INFLUENCE OF SOME NEW BETA-SYMPATHOTROPIC AGENTS ON LIPID MOBILIZATION IN VITRO.

Authors:  D SCHUSTEROVA; D KRCIKOVA; E MUEHLBACHOVA; S HYNIE; M WENKE
Journal:  Int J Neuropharmacol       Date:  1964-04

2.  An infarct-like myocardial lesion and other toxic manifestations produced by isoproterenol in the rat.

Authors:  G RONA; C I CHAPPEL; T BALAZS; R GAUDRY
Journal:  AMA Arch Pathol       Date:  1959-04

3.  The determination of glycogen in liver and muscle by use of anthrone reagent.

Authors:  N V CARROLL; R W LONGLEY; J H ROE
Journal:  J Biol Chem       Date:  1956-06       Impact factor: 5.157

Review 4.  Myocardial ischemia (first of three parts).

Authors:  L D Hillis; E Braunwald
Journal:  N Engl J Med       Date:  1977-04-28       Impact factor: 91.245

5.  Factors influencing infarct size following experimental coronary artery occlusions.

Authors:  P R Maroko; J K Kjekshus; B E Sobel; T Watanabe; J W Covell; J Ross; E Braunwald
Journal:  Circulation       Date:  1971-01       Impact factor: 29.690

Review 6.  Myocardial infarction size: measurement and modification.

Authors:  J A Cairns
Journal:  Can Med Assoc J       Date:  1977-08-06       Impact factor: 8.262

7.  The effect of pregnancy and lactation on the development of experimental heart lesions.

Authors:  E Faltová; M Mráz; J Procházka; J Sedivý
Journal:  Physiol Bohemoslov       Date:  1980

8.  The effect of hypoglycemia on myocardial ischemic injury during acute experimental coronary artery occlusion.

Authors:  P Libby; P R Maroko; E Braunwald
Journal:  Circulation       Date:  1975-04       Impact factor: 29.690

9.  Studies on isoprenaline-induced myocardial lesions. 1. Quantitative evaluation by mercurascan uptake.

Authors:  E Faltová; M Mráz; L Kronrád; L Protivová; J Sedivý
Journal:  Basic Res Cardiol       Date:  1977 Sep-Oct       Impact factor: 17.165

10.  Protective effect of isoprenaline pretreatment on the cardiotoxic effect of the same drug.

Authors:  E Faltová; M Mráz; J Sedivý
Journal:  Physiol Bohemoslov       Date:  1983
View more
  3 in total

1.  The role of myocardial glycogen content for the development of isoprenaline-induced myocardial lesions in different inbred strains of rats.

Authors:  M Mráz; V Kren; D Krsiaková; A Vrána; S Hynie
Journal:  Basic Res Cardiol       Date:  1995 Nov-Dec       Impact factor: 17.165

2.  Heart glycogen content and isoprenaline-induced myocardial lesions.

Authors:  M Mráz; S Hynie
Journal:  Mol Cell Biochem       Date:  1996 Oct-Nov       Impact factor: 3.396

3.  Exercise training, indomethacin, and isoproterenol-induced myocardial necrosis in the rat.

Authors:  G R Brodowicz; D R Lamb
Journal:  Basic Res Cardiol       Date:  1991 Jan-Feb       Impact factor: 17.165

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.